● Recruiting

A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term Hypoparathyroidism

Condition: Hypoparathyroidism · Sponsor: Ascendis Pharma A/S

PhasePhase 3

Planned participants12

Who can joinAll sexes, 12 Years to 18 Years

Healthy volunteersNo

About this study

This trial will enroll adolescents between ages of ≥12 and \<18 years with clinically diagnosed hypoparathyroidism . The purpose of the study is to see how well treatment with once-daily palopegteriparatide works and how safe it is. At least 12 participants will receive palopegteriparatide for 234 weeks. This trial will be conducted in Europe.

This description comes directly from the study's public registry record.

Talk to the study team

Ascendis Registry Inquiries · +45 61242484 · asnd_registryinquiries@ascendispharma.com

Always discuss trial participation with your own doctor first.

Locations (3)

Ascendis Pharma Investigational Site	Bron, France	Recruiting
Ascendis Pharma Investigational Site	Le Kremlin-Bicêtre, France	Recruiting
Ascendis Pharma Investigational Site	Lodz, Poland	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07706764